Judd Salamat, DO
Interventional Cardiology · Portland, ORNPI 1912139411
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $9,879 of the $15,321 with a category attached, or 64.5%. 27 manufacturers reported payments, led by Medtronic at 39.7% of the total. Reporting peaked in 2024 at $9,451 and has fallen 97.7% since, to $216 in 2025.
Across 191 payments — averaging $80.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Abbott$5K
- Abiomed$2K
- Philips North America LLC$323
- Shockwave Medical, Inc$304
- Cardiovascular Systems Inc.$221
- plus $1K from 21 others
What the payments were for
- Travel & lodging$9,87964%
- Food & beverage$5,39635%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 24 | $6,082 |
| Abbott | 34 | $4,854 |
| Abiomed | 30 | $2,250 |
| Philips North America LLC | 13 | $323 |
| Shockwave Medical, Inc | 4 | $304 |
| Cardiovascular Systems Inc. | 14 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $216 |
| Johnson & Johnson | 7 | $136 |
| Endologix LLC | 2 | $134 |
| Novartis | 8 | $123 |
| AstraZeneca | 9 | $101 |
| Boehringer Ingelheim | 5 | $84 |
| EKOS Corporation | 2 | $63 |
| Boston Scientific | 3 | $60 |
| Penumbra, Inc. | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Cardiva Medical, Inc. | 1 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $34 |
| Terumo Medical Corporation | 1 | $33 |
| Chiesi USA, Inc. | 2 | $29 |
| Stryker | 1 | $23 |
| Cook Medical LLC | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XACT$2,928
- Impella$1,400
- ACCULINK$746
- Resolute$138
- SYMPLICITY G3$116
- Dragonfly OCT$114
- RESOLUTE ONYX$114
- SUPERA$113
- EMBOSHIELD NAV6$110
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$108
- Xact carotid stent system$101
How this compares
$15,321 in reported general payments places this provider in the 70th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $226,407 |
| XareltoRivaroxaban | 139 | $158,496 |
| EntrestoSacubitril/Valsartan | 45 | $73,761 |
| Repatha SureclickEvolocumab | 44 | $35,884 |
| Praluent PenAlirocumab | 33 | $22,288 |
| JardianceEmpagliflozin | 13 | $13,405 |
| Rosuvastatin Calcium | 369 | $5,471 |
| Metoprolol Succinate | 362 | $4,367 |
| Atorvastatin Calcium | 212 | $2,564 |
| Cilostazol | 85 | $2,208 |
| ClopidogrelClopidogrel Bisulfate | 199 | $2,123 |
| Ezetimibe | 59 | $1,962 |
| Carvedilol | 138 | $1,757 |
| Spironolactone | 129 | $1,349 |
| Lisinopril | 151 | $1,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $136 | $158,496139 claims |
| NovartisEntresto | $123 | $73,76145 claims |
| Boehringer IngelheimJardiance | $84 | $13,40513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Portland
- Jason WollmuthPortland$749K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
- Harsh GolwalaPortland$105K
- Brandon JonesPortland$101K
- Kathryn DawsonPortland$57K
- Logan VincentPortland$42K
- Amged AbdelazizPortland$38K
- Richard SohnPortland$38K
- Daniel FeldmanPortland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.